Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0752W HIGH $3.44
Volume
9.19 M
Value Traded
9.03 M
Short % Float
16.56%
-26.84%Week
+47.41%1 Month
+30.07%3 Month
+24.37%6 Month
-95.39%5 Year
-92.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
618.55 M
EPS (TTM)
-0.42
P/E Ratio
-
Ent. Value
1.03 B
Total Shares
310.72 M
Float Shares
285.14 M
Insiders
8.27%
Institutions
53.89%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PACB Catalyst Timeline
Dated clinical, regulatory and corporate events for Pacific Biosciences of California, Inc.
Past FDA Catalysts and PDUFA Decisions
How PACB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Pacific Biosciences of California, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PACB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| unexplained subfertility and recurrent pregnancy loss | 2026-05-11 | participants: 96; couples: 47; individuals: 2; genomic findings: approximately one in 10 couples; likely diagnostic findings: 4.8% of individualsRead More | HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy LossRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gibson James R IIOfficer (See Remarks) | Option | 500,000 1,745,663 held | $1.18 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PACB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.1 % | 1.22 M | 723.77 K |
PACB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PACB ranks across every disease it competes in
Competitive Position is a premium feature
See how PACB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPACB News
PACB▼ -2.9%today
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
PacBio has announced that it will hold its quarterly conference call on November 4, 2026, to discuss its third quarter financial results. The call will be accessible via webcast on the company's investor relations website. This event highlights PacBio's commitment to transparency and investor engagement.
Read more →PACB▼ -10.4%on this news
PacBio Announces Second Quarter 2026 Financial Results
PacBio reported its second quarter 2026 financial results, revealing a revenue of $39.0 million, driven by consumables and new system placements. The company has initiated a global rollout of its SPRQ-Nx chemistry, enhancing its sequencing capabilities. However, it also faced a net loss of $44.7 million, reflecting increased operational costs and restructuring efforts.
Read more →PACBPacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
PacBio will participate in the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event will feature a fireside chat with management, aimed at engaging investors. A live webcast will be available, with a replay accessible for 30 days post-event. PacBio specializes in advanced sequencing solutions for various research applications.
Read more →PACBPacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PacBio has announced that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on August 5, 2026. The call is set to take place at 4:30 p.m. Eastern Time and will be accessible via webcast. This event reflects the company's commitment to keeping investors informed about its financial performance.
Read more →PACBPacBio to Participate in the Jefferies Global Healthcare Conference 2026
PacBio will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York and will be accessible via a live webcast. PacBio is known for its high-quality sequencing solutions aimed at resolving complex genetic issues across various research applications.
Read more →PACB▲ +5%on this newsshared move
PacBio to Participate in the Jefferies Global Healthcare Conference
PacBio will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026. The event will take place in New York and will be accessible via a live webcast. This participation highlights PacBio's commitment to sharing advancements in sequencing technology with the healthcare community.
Read more →PACBBlank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
Blank Bio has announced a $7.2 million seed financing and a strategic collaboration with PacBio to enhance RNA foundation models for precision oncology. The partnership aims to generate high-resolution long-read RNA sequencing data from patient tumor samples, which will improve patient-level predictions and biomarker discovery. The funding will support ongoing model development and collaborations in the oncology field.
Read more →PACBHiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
PacBio announced a significant study from the HiFi Solves Sub-fertility Consortium, utilizing HiFi long-read sequencing to investigate unexplained subfertility and recurrent pregnancy loss. The study involved 96 participants across Asia-Pacific and demonstrated the ability of HiFi sequencing to provide comprehensive genetic insights. Findings suggest that this approach could reduce the need for sequential testing and support informed reproductive counseling.
Read more →PACBPacBio Announces First Quarter 2026 Financial Results
PacBio reported its financial results for Q1 2026, highlighting a significant increase in consumable revenue due to the growing adoption of its HiFi technology. The company has expanded its beta program and secured a major collaboration with Basecamp Research for the Trillion Gene Atlas. However, instrument revenue fell short of expectations, impacting overall financial performance.
Read more →PACBPacBio to Report First Quarter 2026 Financial Results on May 7, 2026
PacBio has announced that it will hold a conference call on May 7, 2026, to discuss its financial results for the first quarter of 2026. The call is scheduled for 4:30 p.m. ET and will be accessible via webcast. The company continues to focus on providing advanced sequencing solutions for various research applications.
Read more →PACBPacBio Announces the Appointment of Chris Gibson to the Board of Directors
PacBio has appointed Dr. Christopher Gibson to its Board of Directors. Dr. Gibson, co-founder of Recursion, brings extensive experience in AI-driven drug discovery and data analytics. His leadership is expected to support PacBio's vision of integrating sequencing technologies with advanced analytics, enhancing their capabilities in biological research and healthcare.
Read more →PACB▲ +5.1%on this newsshared move
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
PacBio has partnered with DNAstack to create the first global federated dataset of HiFi whole genome sequencing data. This initiative, part of the HiFi Solves Global Consortium, allows secure international research while keeping sensitive data under institutional control. The collaboration aims to enhance rare disease research by connecting over 10,000 genome sequences from institutions across 15 countries, improving the accuracy of variant detection and accelerating discoveries.
Read more →PACBPacBio Joins iHope Initiative as First Long-Read Genomic Sequencing Partner
PacBio has partnered with the iHope initiative to integrate its HiFi long-read whole-genome sequencing into iHope's global rare disease genomics program. This collaboration aims to improve diagnostic clarity for patients with rare genetic disorders by providing comprehensive genomic insights. The integration is set to begin in early 2026, enhancing the capabilities of iHope's extensive testing network.
Read more →PACBPacBio Announces Fourth Quarter and Full Year 2025 Financial Results
PacBio reported its financial results for Q4 and FY 2025, highlighting a revenue increase to $44.6 million in Q4 2025, up from $39.2 million in Q4 2024. Despite this growth, the company faced a significant net loss of $40.4 million in Q4 2025. The annual results also reflected an increase in net loss, totaling $546.4 million for the year, compared to a net loss of $309.9 million in 2024. The company emphasized its growth in consumables and strategic collaborations aimed at advancing genomic testing.
Read more →PACBPacBio Completes Sale of Short-Read Sequencing Assets
PacBio has completed the sale of its short-read sequencing assets to Illumina for $48.1 million. This strategic move allows PacBio to concentrate on its long-read sequencing technology, which is anticipated to enhance growth opportunities. The transaction closed on January 30, 2026, and includes a non-exclusive license back to PacBio for certain intellectual property.
Read more →PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On
Pacific Biosciences of California, Inc. has completed an asset sale to Illumina Cambridge Limited, receiving $50 million in cash and retaining a non-exclusive license for certain intellectual property. The transaction involved the sale of assets related to the company's short-read DNA sequencing technology. Following the asset sale, the company's pro forma financial statements reflect adjustments for the asset's impact on their financial position and operating results as of September 30, 2025. Despite the cash inflow, PacBio continues to experience significant net losses.
Read more →PACB▼ -7.4%on this news· ran to -20% by day 3shared move
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
PacBio has announced a quarterly conference call to discuss its fourth quarter and full year 2025 financial results, scheduled for February 12, 2026. The call will be accessible via webcast on the company's investor relations website. This event highlights PacBio's commitment to transparency and investor engagement.
Read more →PACB▲ +6%on this news· ran to +17% by day 1shared move
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
PacBio has announced that its HiFi whole-genome sequencing will be the primary method used to investigate Sudden Unexplained Death in Childhood (SUDC) in a research project involving 200 families. This approach aims to improve diagnostic yield by accurately detecting complex genetic variants. The initiative is supported by the SUDC Foundation and aims to provide families with clearer answers regarding the genetic factors contributing to SUDC.
Read more →About Pacific Biosciences of California, Inc.
Headquarters1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025
BIOPHARMAWATCH ELITE PLUS
Trade the next PACB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime